We Introduce UroGen Pharma and Discuss Its Pipeline of Products

Presenting UroGen Pharma
UroGen Pharma (URGN) focuses on cancers and urologic diseases. It announced its fourth quarter and full-year ended December 31, 2019 financial results. The announcement started with Liz Barrett, President and Chief Executive Officer (CEO) of UroGen who stated that the firm is waiting for the approval of its product UGN-101 designed and developed for low-grade upper . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.